Nephros

Nephros Long-term Debt

The Long-Term Debt of Nephros (NEPH) as of Oct 31, 2026 is 1,000.00 USD. In the previous year, Long-Term Debt was 95,000.00 USD — a change of -98.95% (lower).

Long-term Debt

1,000.00USD

YoY

-98.95%

Last updated:

Long-Term Debt of Nephros is 2022 1,000.00 USD. Long-Term Debt of Nephros was 2021 95,000.00 USD. It decreases by -98.95% lower compared to the previous year.

The Nephros Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2016
838,000.00 USD
Jan 1, 2017
954,000.00 USD
Jan 1, 2018
843,000.00 USD
Jan 1, 2019
623,000.00 USD
Jan 1, 2020
846,000.00 USD
Jan 1, 2021
95,000.00 USD
Jan 1, 2022
1,000.00 USD
The Nephros Long-term Debt history
YEARLong-term DebtYoY
1,000.00USD-98.95%
95,000.00USD-88.77%
846,000.00USD+35.79%
623,000.00USD-26.10%
843,000.00USD-11.64%
954,000.00USD+13.84%
838,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nephros Stock analysis

What does Nephros do? Nephros, Inc. generates revenue through its Water Filtration and Renal Products segments. The Water Filtration segment sells high-performance water purification filters for hospitals, healthcare facilities, dialysis centers, commercial facilities, military, and outdoor recreation markets. The Renal Products segment offers a second-generation hemodiafiltration system for end-stage renal disease patients. Products include ultrafiltration systems used in medical and commercial applications, with subsidiaries Biocon 1, LLC, Aether Water Systems, LLC, and Specialty Renal Products, Inc. supporting sales and development. The company's water filtration products are sold to hospitals, dialysis centers, and commercial facilities, while the hemodiafiltration system targets healthcare providers treating ESRD patients. Subsidiaries handle specialized development and distribution, ensuring market coverage across medical and commercial sectors. Revenue streams are derived from both segments, with products serving healthcare infrastructure and renal treatment needs. Nephros, Inc. focuses on medical device solutions for renal disease and water purification, leveraging its subsidiaries to expand market reach. The Water Filtration segment serves healthcare and commercial clients, while the Renal Products segment addresses ESRD treatment through advanced hemodiafiltration technology, creating a diversified revenue model. Nephros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nephros stock

Long-Term Debt of Nephros is 1,000.00 USD in 2022.

Long-Term Debt of Nephros changed from 95,000.00 USD to 1,000.00 USD, representing a -98.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Nephros since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Nephros historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Nephros

All Key Metrics — Nephros